SecurityATRC / AtriCure, Inc. (04963C209)
IndustrySurgical and Medical Instruments and Apparatus
Common Shares Outstanding35,361,743 shares (as of 2018-06-30)
Total Insiders18
Total Directors12
Total Officers7

Stock Insider Trading (from SEC Form 4)

AtriCure, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

ATRC / AtriCure, Inc. insiders include Krell Elizabeth D, Hooven Michael D, LUX ANDREW L, Seith Douglas J, JOHNSTON RICHARD M, Noznesky Justin J, WEHRWEIN SVEN, WHITE ROBERT S., GROVES REGINA E, Wade M. Andrew, Lanning Mark R, JOHNSON B KRISTINE, CARREL MICHAEL H, Privitera Salvatore, and Collar Mark A, ROBARDS KAREN P, Kennedy Patricia J Drake Scott William, .

Insider Roster

Insider Dir Off 10% Shares Owned
Noznesky Justin J SVP, Mktg & Business Develop
X 124,920
Privitera Salvatore Chief Technology Officer
X 82,828
Seith Douglas J Chief Operating Officer
X 258,206
CARREL MICHAEL H President, CEO, & Director, Director
X X 712,796
Wade M. Andrew SVP and CFO
X 180,370
Collar Mark A Director
X 72,198
JOHNSON B KRISTINE Director
X 21,462
GROVES REGINA E Director
X 20,962
WHITE ROBERT S. Director
X 13,826
WEHRWEIN SVEN Director
X 11,026
Lanning Mark R Director
X 106,026
Drake Scott William Director
X 22,026
Krell Elizabeth D Director
X 19,967
LUX ANDREW L SVP, Ops & Quality
X 66,549
JOHNSTON RICHARD M Director
X 5,805
Hooven Michael D Director
X 553,892
ROBARDS KAREN P Director
X
Kennedy Patricia J VP and GM, International
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-08-15 4 Noznesky Justin J S D 30.32 -4,000 124,920 3,787,574
2018-07-24 4 Privitera Salvatore F D 28.49 -4,346 82,828
2018-06-29 4 Wade M. Andrew A D 15.70 613 180,370
2018-06-29 4 CARREL MICHAEL H A D 15.70 900 712,796
2018-06-29 4 Seith Douglas J A D 15.70 967 258,206
2018-06-14 4 Collar Mark A S D 25.00 -2,090 72,198 1,804,950
2018-05-31 4 GROVES REGINA E A D 5,272 20,962
2018-05-31 4 JOHNSON B KRISTINE A D 5,272 21,462
2018-05-30 4 Noznesky Justin J G D -3,000 128,920
2018-05-22 4 Collar Mark A A D 5,221 74,288
2018-05-22 4 Drake Scott William A D 5,221 22,026
2018-05-22 4 GROVES REGINA E A D 5,221 15,690
2018-05-22 4 JOHNSON B KRISTINE A D 5,221 16,190
2018-05-22 4 Lanning Mark R A D 5,221 106,026
2018-05-22 4 WEHRWEIN SVEN A D 5,221 11,026
2018-05-22 4 WHITE ROBERT S. A D 5,221 13,826
2018-05-15 4 Noznesky Justin J S D 23.05 -4,000 131,920 3,040,756
2018-05-16 4 CARREL MICHAEL H G D -325 711,896
2018-05-08 4 Krell Elizabeth D S D 22.82 -10,000 19,967 455,647
2018-05-07 4 Krell Elizabeth D M D 9.30 10,000 29,967
2018-03-13 4 Krell Elizabeth D S D 20.00 -10,000 19,967 399,340
2018-03-12 4 Krell Elizabeth D M D 14.17 10,000 29,967
2018-03-01 4 Seith Douglas J F D 17.71 -19,677 257,239
2018-03-01 4 Seith Douglas J A D 35,996 276,916
2018-03-01 4 Wade M. Andrew F D 17.71 -14,969 179,757
2018-03-01 4 Wade M. Andrew A D 35,996 194,726
2018-03-01 4 CARREL MICHAEL H F D 17.71 -19,740 712,221
2018-03-01 4 CARREL MICHAEL H A D 95,285 731,961
2018-03-01 4 Noznesky Justin J F D 17.71 -14,803 135,920
2018-03-01 4 Noznesky Justin J A D 25,726 150,723
2018-03-01 4 Privitera Salvatore A D 21,174 87,174
2018-03-02 4 Lanning Mark R M D 10.10 10,000 100,805
2018-03-01 4 Drake Scott William P D 17.64 11,000 16,805 296,440
2018-03-01 4 GROVES REGINA E P D 17.43 1,000 10,469 182,475
2018-02-15 4 Noznesky Justin J S D 17.03 -4,000 124,997 2,128,699
2018-01-24 4 CARREL MICHAEL H F D 17.55 -33,167 636,676
2018-01-24 4 Seith Douglas J F D 17.55 -3,275 240,920
2018-01-24 4 Wade M. Andrew F D 17.55 -3,791 158,730
2018-01-18 4 Collar Mark A M D 13.31 25,000 69,067
2018-01-06 4 Noznesky Justin J F D 17.99 -3,182 128,997
2017-12-29 4 CARREL MICHAEL H A D 15.50 547 669,843
2017-12-29 4 Seith Douglas J A D 15.50 328 244,195
2017-12-29 4 Wade M. Andrew A D 15.50 571 162,521
2017-11-28 4 CARREL MICHAEL H G D -1,400 669,296
2017-11-30 4 Wade M. Andrew S D 18.41 -2,000 161,950 2,981,500
2017-11-30 4 Wade M. Andrew M D 11.65 2,000 163,950
2017-11-08 4 JOHNSON B KRISTINE P D 18.36 1,500 10,969 201,391
2017-09-14 4 Collar Mark A M D 13.31 25,000 44,067
2017-08-22 4 Krell Elizabeth D S D 22.40 -10,000 19,967 447,261
2017-08-21 4 Krell Elizabeth D M D 8.04 10,000 29,967
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

Related News Stories

AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates

2018-08-01 zacks
AtriCure (ATRC - Free Report) just came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items. (6-0)

Beauty Lies In The Eye Of The Investor - Cramer's Mad Money (7/19/18)

2018-07-20 seekingalpha
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, July 19. (26-3)

Stocks To Watch: More Trade Tiffs And Stress Tests

2018-06-23 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Trade battles are set to dominate another week's action, with a set of hair-trigger responses from former trade allies leading world news though threatened tariffs are still small in the face of a $20T U. (1297-2)

AtriCure's (ATRC) CEO Mike Carrel on Q1 2018 Results - Earnings Call Transcript

2018-04-29 seekingalpha
Good afternoon, and welcome to AtriCure's First Quarter 2018 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes. (3-0)